Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Inventiva S.A. American Depository Shares (IVA)

https://www.inventivapharma.com

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/10/2020

Market Cap

115,216,387

Shares Outstanding

52,120,000

Weighted SO

51,646,692

Total Employees

N/A

Upcoming Earnings

03/27/2024

Similar Tickers

MLYS --.--%

ELYM --.--%

ANEB --.--%

JANX --.--%

RZLT --.--%

GLUE --.--%

NAMS --.--%

CGEM --.--%

CMPX --.--%

Beta

1.0100

Last Div

0.0000

Range

2.09-4.75

Chg

-0.0500

Avg Vol

11824

Mkt Cap

115216387

Exch

NASDAQ

Country

FR

Phone

33 3 80 44 75 00

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

4.5143

EV Multiple

-1.1297

P/FV

-2.9935

Div Yield %

0.0000

P/E

-0.8798

PEG

-0.0236

Payout

0.0000

Current Ratio

0.9523

Quick Ratio

0.9440

Cash Ratio

0.5367

DSO

247.5092

DIO

149.6608

Op Cycle

397.1699

DPO

13522.9449

CCC

-13125.7750

Gross Margin

0.9561

Op Margin

-4.4342

Pretax Margin

-4.7411

Net Margin

-4.7673

Eff Tax Rate

-0.0057

ROA

-1.5972

ROE

5.5046

ROCE

-5.4112

NI/EBT

1.0055

EBT/EBIT

1.0692

EBIT/Rev

-4.4342

Debt Ratio

0.4461

D/E

-0.9503

LT Debt/Cap

-3.7461

Total Debt/Cap

-19.1328

Int Coverage

-52.2963

CF/Debt

-2.6462

Equity Multi

-2.1304

Rec Turnover

1.4747

Pay Turnover

0.0270

Inv Turnover

2.4388

FA Turnover

2.5384

Asset Turnover

0.3350

OCF/Share

-1.6773

FCF/Share

-1.6884

Cash/Share

0.5546

OCF/Sales

-3.5235

FCF/OCF

1.0066

CF Coverage

-2.6462

ST Coverage

-15.6169

CapEx Coverage

-151.1370

Div&CapEx Cov

-151.1370

P/BV

-2.9935

P/B

-2.9935

P/S

4.5143

P/E

-0.8798

P/FCF

-1.2728

P/OCF

-1.1904

P/CF

-1.1904

PEG

-0.0236

P/S

4.5143

EV Multiple

-1.1297

P/FV

-2.9935

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 01, 21:00 Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée GlobeNewswire Inc. Apr 01, 21:00 Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis GlobeNewswire Inc. May 30, 06:30 Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires GlobeNewswire Inc. May 30, 06:30 Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 GlobeNewswire Inc. May 30, 06:30 Combined General Meeting of June 20, 2024 - Availability of the preparatory documents GlobeNewswire Inc. May 30, 06:30 Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024

Revenue Product Segmentation